{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-24-000064","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2024-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.178298+00:00","generated_at":"2026-05-31T13:34:07.709410+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ligand Pharmaceuticals announces departure of President and COO Matthew Korenberg","bullets":["Korenberg's employment ends no later than October 31, 2024; he may resign earlier in writing.","Severance includes base salary through termination, 50% of 2024 target bonus, and COBRA coverage through Dec 31, 2024.","Post-termination consulting agreement pays $47,808/mo through Oct 31, 2024, then reduced amounts.","Stock award vesting continues through consulting period; unvested awards through Dec 31, 2025 accelerate on consulting end.","Korenberg can exercise stock awards through March 1, 2026, subject to conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-24-000064","json":"https://secwatch.observer/filing/0000886163-24-000064.json","markdown":"https://secwatch.observer/filing/0000886163-24-000064.md","text":"https://secwatch.observer/filing/0000886163-24-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000064/0000886163-24-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000064/lgnd-20240802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:34:07.709410+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"984efd1a15","claim":"Matthew Korenberg departed as President and Chief Operating Officer at LIGAND PHARMACEUTICALS INC.","evidence_excerpt":"On August 2, 2024, Ligand Pharmaceuticals Incorporated (the “Company”) announced that its President and Chief Operating Officer, Matthew Korenberg, will be departing from the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000064/0000886163-24-000064-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will be departing"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}